Numat Technologies NuMat Technologies Closes $12.4M Funding Round to Accelerate Commercialization of Molecularly Engineered Products
April 26, 2018
Previous PostPoseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer
Next PostPoseida raises $30.5 million for cancer cell therapy
